Why Aditxt Shares Are Rallying Today?

Aditxt Inc's  (NASDAQ: ADTX ) therapeutic program Adimune has completed a toxicology study indicating a favorable safety profile  of ADI-100 for rejection of transplanted organs, skin allografting, autoimmune diseases, and allergies. The company says the completion of preclinical toxicity study of ADI-100, potentially a psoriasis drug candidate advances it closer to human ... Full story available on Benzinga.com